Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey |
Durnali, Ayse
(Medical Oncology Department of Dr A.Y.Ankara Oncology Training and Research Hospital)
Tokluoglu, Saadet (Medical Oncology Department of Guven Hospital) Ozdemir, Nuriye (Medical Oncology Department of Ankara Numune Training and Research Hospital) Inanc, Mevlude (Medical Oncology Department of Erciyes University Faculty of Medicine) Alkis, Necati (Medical Oncology Department of Dr A.Y.Ankara Oncology Training and Research Hospital) Zengin, Nurullah (Medical Oncology Department of Ankara Numune Training and Research Hospital) Sonmez, Ozlem Uysal (Medical Oncology Department of Dr A.Y.Ankara Oncology Training and Research Hospital) Kucukoner, Mehmet (Medical Oncology Department of Dicle University Faculty of Medicine) Anatolian Society of Medical Oncology (ASMO), Anatolian Society of Medical Oncology (ASMO) (Anatolian Society of Medical Oncology (ASMO)) |
1 | Hempling RE, Piver MS, Baker TR (1995). Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin(adriamycin) and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective tiral. Am J Clin Oncol, 18, 282-6. DOI |
2 | Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A (2008). Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001. Gynecol Oncol, 111, 74-81. DOI ScienceOn |
3 | Kokawa K, Nishiyama K, Ikeuchi M, et al (2006). Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990-2003). Int J Gynecol Cancer, 16, 1358-63. DOI |
4 | Livi L, Paiar F, Shah N, et al (2003). Uterine sarcoma: twentyseven years of experience. Int J Radiat Oncol Biol Phys, 57, 1366-73. DOI ScienceOn |
5 | Major FJ, Blessing JA, Silverberg SG, et al (1993). Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer, 71, 1702-9. DOI |
6 | Matoda M, Takeshima N, Nomura H, et al (2011). The treatment of uterine leimyosarcoma: clinical outcomes of 18 cases and the efectiveness of chemotherapy. Eur J Gynaecol Oncol, 32, 647-50. |
7 | Menczer J, Levy T, Piura B, et al (2005). A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol, 97, 166-70. DOI |
8 | Odunsi K, Moneke V, Tammela J, et al (2004). Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long term follow up. Int J Gynecol Cancer, 14, 659-64. DOI |
9 | Olah KS, Dunn JA, Gee H (1992). Leimyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynecol, 99, 590-4. DOI |
10 | Olah KS, Gee H, Blunt S, et al (1991). Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer, 27, 1095-9. DOI |
11 | Omura GA, Bleesing JA, Major F, et al (1985). A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol, 3,1240-5. DOI |
12 | Park J-Y, Kim D-Y, Suh D-S, et al (2008). Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol, 134, 1277-87. DOI |
13 | Pautier P, Genestie C, Rey A, et al (2000). Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer, 88, 1425-31. DOI |
14 | Peters WA 3rd, Kumar NB, Fleming WP, Morley GW (1984). Prognostic features of sarcomas and mixed tumors of the endometrium. Obstet Gynecol, 63, 550-6. |
15 | Prat J (2009). FIGO staging for uterine sarcomas. Int J Gynecol Obstet, 104, 177-8. DOI ScienceOn |
16 | Rovirosa A, Ascaso C, Ordi J, et al (2002). Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. Int J Radiat Oncol Biol Phys, 52, 1320-9. DOI |
17 | Schwartz SM, Thomas DB (1989). A case-control study of risk factorsfor sarcomas of the uterus. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer, 64, 2487-92. DOI ScienceOn |
18 | Sagage S, Yamashita K, Ishioka S, et al (2004). Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology, 67, 33-9. DOI |
19 | Salazar OM, Dunne ME (1980). The role of radiation therapy in the management of uterine sarcomas. Int J Radiat Oncol Biol Phyis, 6, 899-902. DOI |
20 | Sartori E, Bazzurini L, Gadducci A, et al (1997). Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol, 67, 70-5. DOI |
21 | Sharma DN, Rath GK, Kumar S, et al (2011). Clinical outcome of patients with uterine sarcomas. J Cancer Res Ther, 7, 270-4. DOI |
22 | Sleijfer S, Seynaeve C, Verweij (2007). Gynaecological sarcomas. Curr Opin Oncol, 19, 492-6. DOI |
23 | Sutton G, Kauderer J, Carson LF, et al (2005). Gynecologic Oncology Group. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 96, 630-4. DOI |
24 | Tavassoli FA, Devilee P (2003). Pathology and Genetics of Tumors of the Breast and Female Genital Organs. World Health Organization Classification of Tumors. Lyon, France: IARC Pres |
25 | Temkin SM, Hellmann M, Lee YC, Abulafia O (2007). Earlystage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer, 17, 215-9. DOI |
26 | Benito V, Lubrano A, Arencibia O, et al (2009). Clinicopathologic analysis of uterine sarcomas from a single institution in the Canary Islands. Int J of Gynecology & Obstetrics, 107,44-9. DOI |
27 | Tsikouras P, Liberis V, Galazios G, et al (2008). Uterine sarcoma: a report of 57 cases over a16-year period analysis. Eur J Gynecol Oncol, 29, 129-34. |
28 | Van Nagell JR Jr, Hanson MB, Donaldson ES, Gallion HH (1986). Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study. Cancer, 57, 1451-4. DOI ScienceOn |
29 | Wolfson AH, Wolfson DJ, Sittler SY, et al (1994). A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol, 52, 56-62. DOI ScienceOn |
30 | Ali S, Wells M (1993). Mixed müllerian tumors of the uterine corpus: a review. Int J Gynecol Cancer, 3, 1-11. DOI |
31 | Benoit L, Arnould L, Cheynel N, et al (2005). The role of surgery and treatment trends in uterine sarcoma. Eur J Surg Oncol, 31, 434-42. DOI |
32 | Chavenic L, Deniaud E, Plancher C, et al (1999). Uterine sarcomas: The Curie Institute experience. Prognosis factors and adjuvant treatments. Gynecol Oncol, 72, 232-7. DOI ScienceOn |
33 | D'Angelo E, Prat J (2010). Uterine sarcomas: A review. Gynecol Oncol, 116, 131-9. DOI |
34 | Echt G, Jepson J, Steel J, et al (1990). Treatment of uterine sarcomas. Cancer, 66, 35-9. DOI ScienceOn |
35 | Einstein MH, Klobocista M, Hou JY, et al (2012). Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecol Oncol, 124, 26-30. DOI ScienceOn |
36 | El Husseiny G, Al Bareedy N, Mourad WA, et al (2002). Prognostic factors and treatment modalities in uterine sarcoma. Am J Clin Oncol, 25, 256-60. DOI |
37 | Gaducci A, Cosio S, Romanini A, Genazzani AR (2008). The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol, 65, 129-42. DOI ScienceOn |
38 | George M, Pejovic MH, Kramar A (1986). Uterine sarcomas: prognostic factors and treatment modalities- study on 209 patients. Gynecol Oncol, 24, 58-67. DOI |
39 | Ghaemmaghami F, Zarchi MK, Gilani MM, et al (2008). Uterine sarcoma: Clinicopathological characteristics, treatment and outcome in Iran. APJCP, 9, 421-6. |